Evaluation of the disintegration properties of commercial famotidine 20 mg orally disintegrating tablets using a simple new test and human sensory test.
The purpose of this study was to demonstrate the usefulness and broad-applicability of a simple disintegration test method for orally disintegrating tablets (ODT). Eight types of commercial famotidine 20 mg orally disintegrating tablets with different physical properties (formulation, manufacturing method, tablet weight, shape, diameter, thickness, etc.), were used. Disintegration times of these tablets were evaluated employing human sensory test, conventional disintegration test, and the new proposed disintegration test. The human sensory test was performed in 5 healthy volunteers. In the conventional disintegration test, the disintegration apparatus described in the Japanese Pharmacopeia (JP 1(st)) was used. Our proposed new test which is characterized by a rotating shaft with a low weight (10, 15 g) and rotation speed (10, 25, 50 rpm) was evaluated using tablets with and without storage under severe conditions (60 degrees C/75%RH for 1 week). The disintegration times of famotidine 20 mg orally disintegrating tablets in human sensory test varied from 9 to 32 s. In contrast, disintegration times in the conventional test were prolonged to over 300 s. Disintegration times in the new proposed test were close to those in human sensory test. Especially, when the new test was conducted with 15 or 10 g weight and 25 rpm, the slope (human sensory test vs. new proposed test) was almost 1. We were able to demonstrate that the new proposed test was useful to estimate the actual human disintegration time.
Harada
Tsutomu
T
Formulation Research Laboratories, Kawashima Research, Eisai Co. Ltd., 1 Kawashimatakahaya-machi, Kakamigahara, Gifu 501-6195, japan. t-harada@hhs.eisai.co.jp
Narazaki
Ryuichi
R
Nagira
Shinsuke
S
Ohwaki
Takayuki
T
Aoki
Shigeru
S
Iwamoto
Kiyoshi
K
D000284:Administration, Oral; D015738:Famotidine / Q000737:chemistry*; D006801:Humans; D012463:Saliva / Q000502:physiology*; D013607:Tablets / Q000737:chemistry*; D013678:Technology, Pharmaceutical / Q000295:instrumentation* / Q000379:methods; D013997:Time Factors
D013607:Tablets; D015738:Famotidine